ICLR
Bearish signalScored 2026-09-23 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
ICON Public Limited Company
- Nom
- ICON Public Limited Company
- Secteur
- Healthcare
- Industrie
- Medical - Diagnostics & Research
- Bourse
- NASDAQ
- Capitalisation
- $14.3B
- Employés
- 40,200
- PDG
- Barry Balfe
- Site web
- https://www.iconplc.com
- Marché
- CRLFTREHNGZYIQVLHMEDP
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 21 444 titres (~3 652 674,44 $ US)
- Insiders
- CLIMAX JOHN DRMcCague Eugene PacelliMurphy Ronan MartinWhitaker Anne ClemO''Neill JulieMurray CiaranGrais LindaBalfe Barry Edward
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,466,664
Avg sell (VWAP, 90d window) $174.41 vs last close $175.57 (+0.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-17
- Liquidity
- Liquid $180,657,834/day · 20d vol
- Last synced
-
2026-09-28 21:10:34
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-17 | McCague Eugene Pacelli | Sell · S | 3,255 | $175.00 | $569,625 | Form 4 |
| 2026-09-17 | Murphy Ronan Martin | Sell · S | 5,005 | $175.00 | $875,875 | Form 4 |
| 2026-09-16 | CLIMAX JOHN DR | Sell · S | 5,005 | $175.00 | $875,875 | Form 4 |
| 2026-08-11 | CLIMAX JOHN DR | Sell · S | 67 | $165.51 | $11,089 | Form 4 |
| 2026-08-11 | Clerkin Nigel Bernard John | Sell · S | 180 | $165.51 | $29,792 | Form 4 |
| 2026-08-11 | Grais Linda | Sell · S | 67 | $165.51 | $11,089 | Form 4 |
| 2026-08-11 | McCague Eugene Pacelli | Sell · S | 67 | $165.51 | $11,089 | Form 4 |
| 2026-08-11 | Murphy Ronan Martin | Sell · S | 67 | $165.51 | $11,089 | Form 4 |
| 2026-08-11 | Murray Ciaran | Sell · S | 212 | $165.51 | $35,088 | Form 4 |
| 2026-08-11 | O'Neill Julie | Sell · S | 73 | $165.51 | $12,082 | Form 4 |
| 2026-08-11 | Whitaker Anne Clem | Sell · S | 67 | $165.51 | $11,089 | Form 4 |
| 2026-08-10 | Balfe Barry Edward | Sell · S | 78 | $165.14 | $12,881 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-14 | Kevin Hern | Sale (Partial) | $15,001 - $50,000 |
| 2026-03-05 | Kevin Hern | Sale (Full) | $100,001 - $250,000 |
| 2026-02-12 | Julia Letlow | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-06-12 | John James | Purchase | $1,001 - $15,000 |
| 2023-01-31 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2021-05-18 | Kevin Hern | Purchase | $100,001 - $250,000 |
| 2020-07-27 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2019-11-07 | Kevin Hern | Purchase | $1,001 - $15,000 |
| 2019-08-07 | Kevin Hern | Purchase | $50,001 - $100,000 |
Signal
Bearish signalScored 2026-09-23 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ICLR presents a deeply concerning financial profile with severe margin compression (net margin collapsing from 9.6% to 2.8%), a deteriorating current ratio approaching 1.0, and a near-total absence of bullish catalysts.
The first sentence of the analysis written for ICLR on 2026-09-23 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 1.10 · operating margin 12%
Suggested stop 168.65, nearest stored support minus 0.5 ATR(3.9% under the last close). Reward/risk to the next stored resistance is 0.02. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 26.4% | 29.4% | 29.6% | 28.6% | 27.5% | |
| Ebit Margin | 5.3% | 13.0% | 11.5% | 10.3% | 6.9% | |
| Ebitda Margin | 10.0% | 18.9% | 18.7% | 18.2% | 13.5% | |
| Operating Profit Margin | 12.3% | 13.3% | 11.8% | 10.3% | 6.9% | |
| Pretax Profit Margin | 3.1% | 10.5% | 7.7% | 7.3% | 3.5% | |
| Continuous Operations Profit Margin | 2.8% | 9.6% | 7.5% | 6.5% | 2.8% | |
| Net Profit Margin | 2.8% | 9.6% | 7.5% | 6.5% | 2.8% | |
| Bottom Line Profit Margin | 2.8% | 9.6% | 7.5% | 6.5% | 2.8% | |
| Current Ratio | 1.096 | 1.263 | 1.207 | 1.200 | 1.186 | |
| Quick Ratio | 1.096 | 1.263 | 1.207 | 1.198 | 1.186 | |
| Solvency Ratio | 0.087 | 0.174 | 0.155 | 0.129 | 0.055 | |
| Cash Ratio | 0.203 | 0.193 | 0.134 | 0.107 | 0.303 | |
| Price To Earnings Ratio | 62.404 | 21.845 | 37.945 | 31.331 | 135.833 | |
| Price To Earnings Growth Ratio | -0.897 | 0.762 | 1.867 | 0.182 | -2.131 | |
| Forward Price To Earnings Growth Ratio | -0.897 | 0.762 | 1.867 | 0.182 | -2.131 | |
| Price To Earnings Diluted Ratio | 62.834 | 22.005 | 38.253 | 31.688 | 137.644 | |
| Price To Earnings Diluted Growth Ratio | -0.903 | 0.765 | 1.846 | 0.184 | -2.153 | |
| Price To Book Ratio | 1.554 | 1.816 | 2.515 | 1.864 | 2.576 | |
| Price To Sales Ratio | 1.732 | 2.089 | 2.862 | 2.046 | 3.792 | |
| Price To Free Cash Flow Ratio | 16.578 | 15.464 | 22.777 | 37.605 | 28.263 | |
| Price To Operating Cash Flow Ratio | 13.791 | 13.444 | 20.017 | 28.115 | 25.067 | |
| Debt To Assets Ratio | 0.219 | 0.213 | 0.232 | 0.281 | 0.325 | |
| Debt To Equity Ratio | 0.387 | 0.378 | 0.426 | 0.568 | 0.700 | |
| Debt To Capital Ratio | 0.279 | 0.274 | 0.299 | 0.362 | 0.412 | |
| Long Term Debt To Capital Ratio | 0.238 | 0.263 | 0.284 | 0.351 | 0.400 | |
| Financial Leverage Ratio | 1.770 | 1.772 | 1.839 | 2.022 | 2.155 | |
| Working Capital Turnover Ratio | 15.874 | 12.548 | 14.445 | 15.472 | 7.605 | |
| Operating Cash Flow Ratio | 0.324 | 0.460 | 0.411 | 0.209 | 0.334 | |
| Operating Cash Flow Sales Ratio | 0.126 | 0.155 | 0.143 | 0.073 | 0.151 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.832 | 0.869 | 0.879 | 0.748 | 0.887 | |
| Debt Service Coverage Ratio | 1.115 | 5.566 | 3.379 | 4.749 | 2.938 | |
| Interest Coverage Ratio | 5.382 | 4.627 | 2.840 | 3.462 | 2.075 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.956 | 43.231 | 10.540 | 10.214 | 15.034 | |
| Operating Cash Flow Coverage Ratio | 0.291 | 0.357 | 0.295 | 0.117 | 0.147 | |
| Capital Expenditure Coverage Ratio | 5.948 | 7.656 | 8.252 | 3.963 | 8.844 | |
| Dividend Paid And Capex Coverage Ratio | 5.948 | 7.656 | 8.252 | 3.963 | 8.844 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 20.883 | 13.020 | 17.615 | 14.429 | 34.726 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 26.4% | ▼-3.0% | ▼-1.9% |
| Ebit Margin | 5.3% | ▼-7.6% | ▼-4.1% |
| Ebitda Margin | 10.0% | ▼-8.9% | ▼-5.9% |
| Operating Profit Margin | 12.3% | ▼-1.0% | ▲1.4% |
| Pretax Profit Margin | 3.1% | ▼-7.4% | ▼-3.4% |
| Continuous Operations Profit Margin | 2.8% | ▼-6.8% | ▼-3.1% |
| Net Profit Margin | 2.8% | ▼-6.8% | ▼-3.1% |
| Bottom Line Profit Margin | 2.8% | ▼-6.8% | ▼-3.1% |
| Current Ratio | 1.096 | ▼-0.167 | ▼-0.095 |
| Quick Ratio | 1.096 | ▼-0.167 | ▼-0.094 |
| Solvency Ratio | 0.086 | ▼-0.087 | ▼-0.033 |
| Cash Ratio | 0.203 | ▲0.010 | ▲0.015 |
| Price To Earnings Ratio | 62.404 | ▲40.559 | ▲4.532 |
| Price To Earnings Growth Ratio | -0.897 | ▼-1.658 | ▼-0.854 |
| Forward Price To Earnings Growth Ratio | -0.897 | ▼-1.658 | ▼-0.854 |
| Price To Earnings Diluted Ratio | 62.834 | ▲40.829 | ▲4.349 |
| Price To Earnings Diluted Growth Ratio | -0.903 | ▼-1.668 | ▼-0.851 |
| Price To Book Ratio | 1.554 | ▼-0.262 | ▼-0.511 |
| Price To Sales Ratio | 1.732 | ▼-0.357 | ▼-0.772 |
| Price To Free Cash Flow Ratio | 16.578 | ▲1.115 | ▼-7.559 |
| Price To Operating Cash Flow Ratio | 13.791 | ▲0.347 | ▼-6.296 |
| Debt To Assets Ratio | 0.219 | ▲0.005 | ▼-0.035 |
| Debt To Equity Ratio | 0.387 | ▲0.008 | ▼-0.105 |
| Debt To Capital Ratio | 0.279 | ▲0.004 | ▼-0.046 |
| Long Term Debt To Capital Ratio | 0.238 | ▼-0.025 | ▼-0.069 |
| Financial Leverage Ratio | 1.770 | ▼-0.003 | ▼-0.142 |
| Working Capital Turnover Ratio | 15.874 | ▲3.326 | ▲2.685 |
| Operating Cash Flow Ratio | 0.324 | ▼-0.136 | ▼-0.024 |
| Operating Cash Flow Sales Ratio | 0.126 | ▼-0.030 | ▼-0.004 |
| Free Cash Flow Operating Cash Flow Ratio | 0.832 | ▼-0.037 | ▼-0.011 |
| Debt Service Coverage Ratio | 1.115 | ▼-4.451 | ▼-2.434 |
| Interest Coverage Ratio | 5.382 | ▲0.755 | ▲1.705 |
| Short Term Operating Cash Flow Coverage Ratio | 1.956 | ▼-41.275 | ▼-14.239 |
| Operating Cash Flow Coverage Ratio | 0.291 | ▼-0.066 | ▲0.050 |
| Capital Expenditure Coverage Ratio | 5.948 | ▼-1.708 | ▼-0.985 |
| Dividend Paid And Capex Coverage Ratio | 5.948 | ▼-1.708 | ▼-0.985 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 20.883 | ▲7.863 | ▲0.749 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $14.29B | $17.30B | $23.24B | $15.84B | $20.78B | |
| Enterprise value | $17.20B | $20.36B | $26.80B | $20.38B | $25.68B | |
| EV / Sales | 2.08x | 2.46x | 3.30x | 2.63x | 4.68x | |
| EV / Op. cash flow | 16.60x | 15.82x | 23.08x | 36.18x | 30.97x | |
| EV / Free cash flow | 19.95x | 18.20x | 26.27x | 48.39x | 34.92x | |
| EV / EBITDA | 20.88x | 13.02x | 17.61x | 14.43x | 34.73x | |
| Net debt / EBITDA | 3.53x | 1.96x | 2.34x | 3.21x | 6.62x | |
| Current ratio | 1.10x | 1.26x | 1.21x | 1.20x | 1.19x | |
| Income quality | 4.52x | 1.63x | 1.90x | 1.11x | 5.41x | |
| Graham number | $88 | $158 | $137 | $121 | $79 | |
| Graham net-net | -$56 | -$57 | -$63 | -$77 | -$104 | |
| Tax burden | 90.8% | 91.1% | 98.1% | 89.5% | 78.8% | |
| Interest burden | 57.3% | 80.8% | 66.7% | 70.8% | 51.3% | |
| Working capital | $305.5M | $734.1M | $585.9M | $538.5M | $462.3M | |
| Invested capital | $12.81B | $13.88B | $13.97B | $14.29B | $14.75B | |
| Return on assets | 1.4% | 4.7% | 3.6% | 2.9% | 0.9% | |
| Operating ROA | 6.1% | 6.5% | 5.6% | 4.6% | 3.6% | |
| Return on tangible assets | 5.3% | 18.6% | 14.9% | 12.8% | 4.2% | |
| Return on equity | 2.5% | 8.3% | 6.6% | 5.9% | 1.9% | |
| Return on invested capital | 6.7% | 7.1% | 6.6% | 4.9% | 2.0% | |
| Return on capital employed | 7.7% | 7.8% | 6.8% | 5.5% | 2.5% | |
| Earnings yield | 1.6% | 4.6% | 2.6% | 3.2% | 0.7% | |
| Free cash flow yield | 6.0% | 6.5% | 4.4% | 2.7% | 3.5% | |
| Capex / Op. cash flow | 16.8% | 13.1% | 12.1% | 25.2% | 11.3% | |
| Capex / Depreciation | 45.5% | 31.8% | 24.0% | 25.0% | 29.8% | |
| Capex / Sales | 2.1% | 2.0% | 1.7% | 1.8% | 1.7% | |
| SG&A / Sales | 9.5% | 8.8% | 9.6% | 10.1% | 10.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.2% | 0.6% | 0.7% | 0.9% | 2.4% | |
| Intangibles / Total assets | 73.6% | 74.7% | 75.8% | 77.1% | 79.1% | |
| Days sales outstanding | 122d | 126d | 130d | 132d | 138d | |
| Days payables outstanding | 47d | 44d | 38d | 40d | 21d | |
| Operating cycle | 122d | 126d | 130d | 133d | 138d | |
| Cash conversion cycle | 75d | 82d | 92d | 92d | 117d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-18 WINTON GROUP Ltd Has $313,000 Holdings in Icon Plc $ICLR WINTON GROUP Ltd cut its stake in Icon Plc (NASDAQ: ICLR) by 94.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,800 shares of the medical research company''s stock after selling 28,754 shares during the period. WINTON
- 2026-08-28 Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue? Icon PLC (ICLR) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-19 A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49 On August 19, 2026, Icon PLC (ICLR) shares rose 3.2% today, closing at $172.49, which is within its 52-week range of $66.57 to $203.91. This recent uptick in sh
- 2026-08-17 Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells Investors On August 17, 2026, Icon PLC (ICLR) shares rose 3.9%, bringing the current price to $169.45. This price is situated within a 52-week range of $66.57 to $203.91,
- 2026-08-11 Oakmark Concentrated Strategy Q2 2026 Performance Review The portfolio''s return was 9.21% (net) for the reporting period. Centene, ICON and Keurig Dr Pepper were the contributors during the quarter. Intercontinental Exchange, Salesforce and ConocoPhillips were the detractors during the quarter.
- 2026-08-06 Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist? ICLR''s discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
- 2026-08-06 ICON Announces Pricing of USD 2.15 Billion Notes DUBLIN--(BUSINESS WIRE)--ICON Announces Pricing of USD 2.15 Billion Notes.
- 2026-08-05 ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen ICON''s 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
- 2026-08-04 ICON Announces Private Offering of Notes DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), intends to offer one or more series of senior notes (the “Notes”), in a private offering (the “Offering”) with registration rights, subject to market and other conditions. The Notes will be guaranteed on a senior unsecured basis by ICON.
- 2026-08-01 Icon Plc $ICLR Shares Sold by Avidity Partners Management LP Avidity Partners Management LP lowered its stake in Icon Plc (NASDAQ: ICLR) by 51.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,000 shares of the medical research company''s stock after selling 17,100 shares during the period. Icon makes up about 0.4%